<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Ann Saudi Med</journal-id>
      <journal-id journal-id-type="publisher-id">ASM</journal-id>
      <journal-title-group>
        <journal-title>Annals of Saudi Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0256-4947</issn>
      <issn pub-type="epub">0975-4466</issn>
      <publisher>
        <publisher-name>Medknow Publications</publisher-name>
        <publisher-loc>India</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">20427948</article-id>
      <article-id pub-id-type="pmc">2886884</article-id>
      <article-id pub-id-type="publisher-id">ASM-30-246b</article-id>
      <article-id pub-id-type="doi">10.4103/0256-4947.62825</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letters</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Fludarabine-induced bradycardia in a patient with refractory leukemia</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Chung-Lo</surname>
            <given-names>Woei</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hsieh</surname>
            <given-names>Ching-Yun</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chiu</surname>
            <given-names>Chang-Fang</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bai</surname>
            <given-names>Li-Yuan</given-names>
          </name>
          <xref ref-type="corresp" rid="cor1"/>
        </contrib>
      </contrib-group>
      <author-notes>
        <corresp id="cor1">Correspondence: Li-Yuan Bai China Medical University Hospital, 2 Yu-Der Road, Taichung, Taiwan</corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>May-Jun</season>
        <year>2010</year>
      </pub-date>
      <volume>30</volume>
      <issue>3</issue>
      <fpage seq="b">246</fpage>
      <lpage>247</lpage>
      <permissions>
        <copyright-statement>&#xA9; Annals of Saudi Medicine</copyright-statement>
        <copyright-year>2010</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
    </article-meta>
  </front>
  <body>
    <p><bold>To the Editor:</bold> A 22-year-old male diagnosed with acute myelogenous leukemia in November 2005 achieved complete remission after two courses of induction chemotherapy with idarubicin (12 mg/m<sup>2</sup> intravenously for 3 days) and cytosine arabinoside (200 mg/m<sup>2</sup> in a 24-hour infusion for 7 days). He then received an additional two courses of cytosine arabinoside (3000 mg/m<sup>2</sup>) in a 3-hour continuous intravenous infusion twice daily for 3 days in April 2006 for intensification. Six months later, the leukemia relapsed and was refractory to re-induction chemotherapy (idarubicin 12 mg/m<sup>2</sup> on days 1-3 and cytosine arabinoside 200 mg/m<sup>2</sup> on days 1-7). With the exception of myelosuppression, no toxic events occurred during idarubicin and cytosine arabinoside treatment. Due to the refractoriness to re-induction chemotherapy, salvage chemotherapy with the FLAGI regimen (fludarabine 30 mg/m<sup>2</sup> on days 1-5, cytosine arabinoside 2000 mg/m<sup>2</sup> on days 1-5, and idarubicin 12 mg/m<sup>2</sup> on days 7-8) was prescribed. Before chemotherapy, his vital signs were stable, with a blood pressure of 111/65 mm Hg, a respiratory rate of 19/min, a heart rate of 97/min, and a body temperature of 36.6&#xB0;C. An electrocardiogram (ECG) showed a normal sinus rhythm (<xref ref-type="fig" rid="F0001">Figure 1a</xref>). Premedication included dexamethasone, granisetron, and metoclopramide, which were prescribed in previous chemotherapy. Thirty minutes after the fludarabine infusion had been started, he developed sudden-onset general weakness, which lessened 5 minutes later. At that time, persistent bradycardia (48 beats per minute) was noted; vital signs were otherwise normal (blood pressure, 120/70 mm Hg; respiratory rate, 20/min; and body temperature, 36.1&#xB0;C). ECG revealed sinus bradycardia but no atrioventricular block, ST segment elevation or depression, or T wave inversion (<xref ref-type="fig" rid="F0002">Figure 1b</xref>). The patient did not have chest tightness or pain, dizziness, cold sweats, palpitations, dyspnea, or fever with chills. Investigations showed serum potassium 4.9 mmol/L (normal, 3.5-4.5 mmol/L), creatinine 1.0 gm/dL (normal, 0.5-1.3 g/dL), CPK 19 IU/L (normal, 38-174 IU/L), creatine kinase MB fraction 2.7 U/L (normal, 3-10 U/L), and troponin I &lt; 0.04 ng/ml (normal, &lt;0.8 ng/mL). No specific therapy was administered; however, oxygen was given at 4 L/min via nasal cannula. The persistent bradycardia resolved gradually, 3 hours after cessation of the 5-day fludarabine infusion (<xref ref-type="fig" rid="F0003">Figure 1c</xref>); he then received 2 days of idarubicin treatment without incident (<xref ref-type="fig" rid="F0004">Figure 2</xref>).</p>
    <fig id="F0001" position="float">
      <label>Figure 1a</label>
      <caption>
        <p>ECG findings before the start of therapy.</p>
      </caption>
      <graphic xlink:href="ASM-30-246-g001"/>
    </fig>
    <fig id="F0002" position="float">
      <label>Figure 1b</label>
      <caption>
        <p>ECG on day 1-5 of fludarabine infusion.</p>
      </caption>
      <graphic xlink:href="ASM-30-246-g002"/>
    </fig>
    <fig id="F0003" position="float">
      <label>Figure 1c</label>
      <caption>
        <p>ECG on the day following infusion of fludarabine.</p>
      </caption>
      <graphic xlink:href="ASM-30-246-g003"/>
    </fig>
    <fig id="F0004" position="float">
      <label>Figure 2</label>
      <caption>
        <p>Correlation between heart rate and FLAGI regimen infusion.</p>
      </caption>
      <graphic xlink:href="ASM-30-246-g004"/>
    </fig>
    <p>Cytosine arabinoside is frequently used in the treatment of hematologic malignancies, especially acute myelogenous leukemia. Sporadic cases of pericarditis, pericardial effusion, cardiac tamponade, congestive heart failure, and sinus bradycardia have previously been reported as complications of cytosine arabinoside.<xref ref-type="bibr" rid="CIT1">1</xref>&#x2013;<xref ref-type="bibr" rid="CIT3">3</xref> Fludarabine is a purine antagonist that is commonly used for patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia. The most common adverse effects are myelosuppression and immunosuppression. Cardiovascular complications of fludarabine are rare, although several cases of congestive heart failure or left ventricular failure have been reported.<xref ref-type="bibr" rid="CIT4">4</xref>&#x2013;<xref ref-type="bibr" rid="CIT5">5</xref></p>
    <p>There are many possible etiologies for the bradycardia seen in the present patient. For example, sepsis, cardiogenic events, electrolyte imbalance, and drugs such as cytosine arabinoside may all cause bradycardia. An adverse drug reaction is considered to be the probable cause of the bradycardia in this patient because no other etiologies were apparent. Cytosine arabinoside seemed an unlikely cause of bradycardia because the patient had received cytosine arabinoside-containing chemotherapy previously. The bradycardia occurred during fludarabine treatment and subsided significantly after completion of the infusion of this drug. Other probable causes of bradycardia had already been excluded and therefore it is reasonable to speculate about a possible relationship between fludarabine and the sinus bradycardia observed in this patient. Clinicians should be aware of this potential toxic effect of fludarabine, especially in view of its increased use in the treatment of hematologic diseases.</p>
  </body>
  <back>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="CIT1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vaickus</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Letendre</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Pericarditis induced by high-dose cytarabine therapy</article-title>
          <source>Arch Intern Med</source>
          <year>1999</year>
          <volume>144</volume>
          <fpage>1868</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">6477012</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Conrad</surname>
              <given-names>ME</given-names>
            </name>
          </person-group>
          <article-title>Cytarabine and cardiac failure</article-title>
          <source>Am J Hematol</source>
          <year>1992</year>
          <volume>41</volume>
          <fpage>143</fpage>
          <lpage>4</lpage>
        </element-citation>
      </ref>
      <ref id="CIT3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stamatopoulos</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kanellopoulou</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Vaiopoulos</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Stamatellos</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Yataganas</surname>
              <given-names>X</given-names>
            </name>
          </person-group>
          <article-title>Evidence for sinoatrial blockade assiciated with high dose cytarabine therapy</article-title>
          <source>Leuk Res</source>
          <year>1998</year>
          <volume>22</volume>
          <fpage>759</fpage>
          <lpage>61</lpage>
          <pub-id pub-id-type="pmid">9680105</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Spriano</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Clavio</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Carrara</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Canepa</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Miglino</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pierri</surname>
              <given-names>I</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Fludarabine in untreated and previously treated B-CLL patients: a report on efficacy and toxicity</article-title>
          <source>Haematologica</source>
          <year>1994</year>
          <volume>79</volume>
          <fpage>218</fpage>
          <lpage>24</lpage>
          <pub-id pub-id-type="pmid">7926970</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ritchie</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Seymour</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>AW</given-names>
            </name>
            <name>
              <surname>Szer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Grigg</surname>
              <given-names>AP</given-names>
            </name>
          </person-group>
          <article-title>Acute left ventricular failure following mephalan and fludarabine conditioning</article-title>
          <source>Bone Marrow Transplant</source>
          <year>2001</year>
          <volume>28</volume>
          <fpage>101</fpage>
          <lpage>3</lpage>
          <pub-id pub-id-type="pmid">11498753</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
